• 沒有找到結果。

Chapter 3: Result

3.3 Quality assessment

Overall, the risk of bias for all studies was generally low, with the exception of the unclear

mentioned of allocation concealment, and blinding of participants and personnel because

of the nature of open-label design. The objective analysis of the efficacy and viral load

measurement were not likely to be disrupted by blinding or not, but the process of

blinding may have been important for assessment of subjective analysis, for examples,

drug-related adverse events. Three studies26-28 assessed with unclear risk on reporting bias,

because those published as an abstract on posters or reports on AIDS conferences with

preliminary or simplistic results. No study assessed the attrition bias for incomplete

outcome data because of high rate of loss to follow-up (Figure 2a, 2b).

We summarized the certainty of evidence findings for three HIV-positive populations;

virally suppressed (Table 3), treatment-naive with stratification of ARV mechanism

(Table 4,5,6) and treatment-experienced (Table 7) by GRADE approach. For the

virological suppression outcomes at 48 weeks, the certainty of evidence was high for

treatment-naive patients when compared to EFV-based regimen, PI-based regimen and

experienced patients. There was moderate quality evidence that both

treatment-naive patients using DTG-based compared to InSTI-based regimen and virally suppressed

patients switched to DTG-based, both did not reached significantly different, contributed

by four and six trials separately. Evidence quality was mainly downgraded for imprecision

because of few clinical events in several studies14-16,25. For tolerability outcomes, the

certainty of evidence was low for most scenarios, mainly downgraded by potential

performance bias because limited by open-label design and imprecise estimates for

limited number of events and wide confidence intervals reported. In contrast, evidence

quality were upgraded one level because of large magnitude of estimated effect with no

plausible confounders while DTG-based compared to EFV-based and PI-based regimen

in treatment-naive patients group.

Chapter 4: Discussion

Although the aspect of cost-benefit considerations and the global health burden

endorsed by international agencies, especially the WHO, there had been more LMICs

large-scale initiative to implement DTG transition programme, switching DTG-based as

the first-line regimen, which is still an importance issues on how likely to perform within

HIV-positive patients. In this meta-analysis, we provided a more comprehensive view of

relative efficacy and tolerability between DTG-based regimen and others combination

ART in three independent scenarios of HIV-positive populations. Our results

demonstrated that HIV virally suppressed patients who was no significant difference rate

of both viral suppression and discontinuation due to any adverse events. For efficacy,

among three studies12,15,16 showed virological benefit were trend toward others

ART-based regimen. Patients in DOLAM15 and ASPIRE16 who were assigned to control group

for non-switching regimen but remained current ART (cART), among patients in

DOLAM mostly with NNRTI-based regimen (71%) at baseline. Patients in NEAT02212

control group were assigned to continue using ritonavir-boosted PI regimen, primarily

ritonavir-boosted darunavir (51%), with TDF/FTC backbone (65%) at baseline. Results

of efficacy demonstrated a robust and well homogeneity, supported by stratification

factors of different follow-up durations. For tolerability, the estimated risk ratios showed

a large effect and higher proportion of discontinuation of study drug related to adverse

events after switched to DTG-based regimen, among three DTG-switch trials12,13,17

shown a well-tolerated aspect on another ART regimen, even there was no significant

difference between both groups at the endpoint. Nevertheless, the particularly notable risk

ratio of discontinuation due to any AEs reported within the DTG-switch arm was

expectable while compared with remaining on a stable baseline regimen that patients have

been well-tolerating from a long period of time. Based on the results that we did not

support a proactive practice to switch the current ART to DTG-based regimen while the

patients were reaching virological suppression, since the risk of switching could outweigh

the benefits. But for specific long-term safety, patients who switched from tenofovir

disoproxil fumarate (TDF) combination to DTG-based regimens was associated with

reduced bone mineral density31 and improved bone turnover markers.17 Moreover, DTG

is likely to be a good substitute therapeutic ART class to LPV/r for HIV patients due to

less likely to dyslipidemia. Patients with those comorbidities that may derive benefit from

being switched to DTG-based regimen. However, in some LMICs had been already

completed the DTG transition programme by amended their national guidelines and prior

preferred standard EFV were no longer available, that is necessary for national healthcare

and provider take caution the emergence of ART discontinuation while patients switching

regimen to DTG-based.

A second sub-population analysis was performed to compare efficacy and tolerability

in treatment-naive patients using DTG-based regimen, could had a significantly better

efficacy up to week 48, either included the study of pregnant women and HIV-associated

TB coinfected patients or not. Sensitivity analyses all showed treatment differences in

favour of the DTG-based regimen and subgroup analysis revealed DTG-based regimen

versus EFV- and PI-based regimen, was associated with a greater proportion of patients

being virally suppressed; versus others InSTI-based regimen with marginally

significantly better, at week 48 after ART initiation, which was partly consistent with the

pooled result by George;32 included two original DTG versus EFV RCTs with

HIV-positive treatment-naive populations. However, we cannot directly contrast the result with

Junjun’s study33, since the misclassification subgroup analysis. There was moderate to

high quality evidences of achieved viral suppression for DTG-based relative to others

mechanisms-based ART in treatment-naive patients. For tolerability, the superior

responses were also driven by a reduction risk to discontinue ART due to any adverse

events in the DTG-based regimen than EFV-based and PI-based regimen, both evidences

was upgraded to high and moderate quality separately, based on the large magnitude of

effect that was observed. Although the comparison to others InSTI-based regimen was no

statistically significant, which was correspond to the large prospective cohort study,34 but

with low quality evidences nevertheless. Overall, our results consistently supported the

WHO 2018 latest guideline suggestion; recommended DTG-based as the preferred

first-line regimen for people living with HIV initiating ART with conditional recommendation.

For DTG-based used in treatment-experienced patients, despite insufficient number of

RCTs included, we found that DTG-based regimen was associated with a significantly

greater proportion of treatment-experienced patients achieving virological suppression,

at the end of 48 weeks after initiated second-line regimen. Our results provided the

efficacy related quality evidence was high certainty; which showed that DTG-based was

an effective ART regimen for second-line among adults for whom a NNRTI- or PI- based

first-line regimen had failed. For tolerability, results also supported DTG-based as an

alternative regimen based on patients in the DTG-based regimen were almost a half times

the risk less likely to discontinue their ART due to any adverse events. On the overall of

our findings, DTG in combination with an optimized backbone was a superior regimen

for treatment-experienced patients with HIV.

Our meta-analysis was included all adequate RCTs and introduced new scenario which

contributed to a consolidated view for DTG-based efficacy and tolerability profile.

However, there were few limitations existed. First, the predominant of the study

characteristics, which may not be fully represented to the global HIV epidemic, since the

mainly completed by white and male adults in developed country settings, typically

limiting the evidences for pregnant women, people with HIV-associated TB and people

with advanced HIV infection. Recent studies also did not consider the integral

circumstances, the people who lived in resource-limited LMICS, where an increasing rate

of NRTI- and NNRTI-transmitted resistance and local people without sufficient medium

of healthcare services,35 for example: HIV viral load monitoring, drug mutation or

resistance testing. Second, tolerability outcome was analyzed considering ART

discontinuations due to any adverse events, but study drug-related adverse events were

not independently reported on each included RCT, thus it may leading to an

overestimation of ART discontinuations rate. Nonetheless, there are several ongoing

RCTs will enable to fit the evidence gaps in the forthcoming year, using DTG-based

regimen with assessment of virologic efficacy and safety of HIV-positive pregnant

women and their infants; VESTED (NCT03048422) and DolPHIN2 (NCT03249181),

switching to DTG-based regimen with dual regimen simplification; DUALIS

(NCT02486133), the more detailed data highlight the HIV-positive patients from LMICs

who failing the first-line regimen; D2EFT (NCT03017872).

In summary, our meta-analyses show that the DTG-based regimens have superior

efficacy and tolerability to EFV- and PI- based regimens for patients who are

treatment-naive, and treatment-experienced patients with virological failure. Conversely, for those

who already achieved virological suppression under other regimens, switch to

DTG-based regimen did not yield a better virological suppression rate by 24-48 weeks.

Furthermore, for this group of patients, switch from a stable regimens to DTG-based

regimens is associated with an inferior tolerability.

Reference

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing hiv infection recommendations for a public health approach,second edition. 2016.

2. Kanters S, Vitoria M, Doherty M et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and

network meta-analysis. The Lancet HIV 2016; 3: e510-e20.

3. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.

Geneva: (WHO/CDS/HIV/18.51). Licence: CC BY-NC-SA 3.0 IGO., 2018.

4. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. Geneva: (WHO/CDS/HIV/18.18).

Licence: CC BY-NC-SA 3.0 IGO., 2018.

5. World Health Organization. Kanters S, Jansen J, Zoratti M, Forrest J, Humphries B, Campbell J. Web Annex B. Systematic literature review and network meta-analysis assessing first-line antiretroviral treatments In: Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and

recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: (WHO/CDS/HIV/18.25). Licence: CC BY-NC-SA 3.0 IGO., 2018.

6. Vineet Prabhu CW, Sarah Jenkins, Saman Nizami, Kelly Catlin, Paul Domanico.

New ARVs Could Represent Over USD 3 Billion in Cost Savings Through 2025.

Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2016.

7. Vitoria M, Ford N, Clayden P et al. When could new antiretrovirals be

recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank. Curr Opin HIV AIDS 2017; 12: 414-22.

8. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.

9. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of

Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.

Available from http://handbook.cochrane.org.

10. Higgins JP, Altman DG, Gotzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.

11. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for

grading quality of evidence and strength of recommendations. Updated October 2013.

The GRADE Working Group, 2013. Available fromguidelinedevelopment.org/handbook.

12. Gatell JM, Assoumou L, Moyle G et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017; 31: 2503-14.

13. Trottier B, Lake JE, Logue K et al. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther 2017; 22: 295-305.

14. Molina J-M, Ward D, Brar I et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a

randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

The Lancet HIV 2018; 5: e357-e65.

15. Blanco JL, Rojas J, Paredes R et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother 2018; 73: 1965-71.

16. Taiwo BO, Marconi VC, Berzins B et al. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot

Randomized Trial. Clin Infect Dis 2018; 66: 1794-7.

17. Llibre JM, Hung C-C, Brinson C et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The

Lancet 2018; 391: 839-49.

18. van Lunzen J, Maggiolo F, Arribas JR et al. Once daily dolutegravir

(S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV:

planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet Infectious Diseases 2012; 12: 111-8.

19. Raffi F, Rachlis A, Stellbrink H-J et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the

randomised, double-blind, non-inferiority SPRING-2 study. The Lancet 2013; 381: 735-43.

20. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.

21. Clotet B, Feinberg J, van Lunzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. The Lancet 2014; 383:

2222-31.

22. Gallant J, Lazzarin A, Mills A et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised

controlled non-inferiority trial. The Lancet 2017; 390: 2063-72.

23. Sax PE, Pozniak A, Montes ML et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet 2017; 390: 2073-82.

24. Orrell C, Hagins DP, Belonosova E et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection

(ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

The Lancet HIV 2017; 4: e536-e46.

25. Sax PE, DeJesus E, Crofoot G et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. The Lancet HIV 2017; 4: e154-e60.

26. C. Orrell KK, J.A. Coombs, A. Amara, L. Myer, J. Kaboggoza. DolPHIN-1 : Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy. 22nd

International AIDS Conference, 2018.

27. Dooley KE, Kaplan R, Mwelase N et al. Dolutegravir-Based Antiretroviral Therapy for Patients Co-Infected with Tuberculosis and Hiv: A Multicenter, Noncomparative, Open-Label, Randomized Trial. Clin Infect Dis 2019.

28. A Cournil CK, S Eymard-Duvernay, S Lem, M Mpoudi-Ngole, P Omgba.

Dolutegravir- versus an efavirenz 400 mg-based regimen for the initial treatment of HIV-infected patients in Camer- oon: 48-week efficacy results of the NAMSAL ANRS 12313 trial. J Int AIDS Soc, 2018.

29. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in

antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. The Lancet 2013;

382: 700-8.

30. Aboud M, Kaplan R, Lombaard J et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. The Lancet Infectious Diseases 2019; 19: 253-64.

31. McComsey GA, Lupo S, Parks D et al. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS 2018; 32: 477-85.

32. Rutherford GW, Horvath H. Dolutegravir Plus Two Nucleoside Reverse

Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.

PLoS One 2016; 11: e0162775.

33. Jiang J, Xu X, Guo W et al. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1

infection: a meta-analysis of randomized controlled trials. AIDS Res Ther 2016; 13: 30.

34. Llibre JM, Montoliu A, Miro JM et al. Discontinuation of dolutegravir,

elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV

Med 2019; 20: 237-47.

35. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance,Geneva Licence: CC BY-NC-SA 3.0 IGO. 2017.

Table 1: PubMed and Embase search strategy, which was modified and adapted as needed for use in the other databases.

Search PubMed query

#3 Search #1 AND #2

#2 HIV Integrase Inhibitors[mh] OR HIV Infections/drug therapy[mh] OR reverse transcriptase inhibitors[mh] OR Antiretroviral Therapy, Highly Active[mh] OR Anti-Retroviral Agents[mh] OR integrase inhibitor*[tw]

OR integrase strand transfer inhibitor*[tw] OR INSTI[tw] OR antiretroviral[tw] OR retroviral[tw] OR HIV*[tw] OR anti-AIDS[tw]

#1 dolutegravir[tw] OR DTG[tw] OR S/GSK1349572[tw] OR GSK-1349572[tw] OR Tivicay[tw] OR dolutegravir[Supplementary Concept]

[mh] = Medical Subject Heading (MeSH) term. [tw] = text word. [pt] = publication type.

Search Embase query

#3 Search #1 AND #2

#2 HIV Integrase Inhibitors OR HIV Infections therapy OR HIV drug therapy OR reverse transcriptase inhibitors OR Antiretroviral Therapy, Highly Active OR Anti-Retroviral Agents OR integrase inhibitor* OR integrase strand transfer inhibitor* OR INSTI OR antiretroviral OR anti-retroviral OR anti-HIV* OR anti-AIDS

#1 dolutegravir OR DTG OR GSK1349572 OR GSK-1349572 OR Tivicay

Table 2: Characteristics of patients included in the selected randomized control trial studies.

Study (Trial name,

publication year) Country Study

design (1) Virological Suppressed:

NEAT022, 2017a Multinational open-label 96wks 48wks 415 DTG+2NRTI PI/s+2NRTI STRIIVING, 2017 USA and

Canada open-label 24wks 24wks 553 DTG+2NRTI cART

SWORD 1+2, 2018 Multinational open-label 48wks 48wks 1024 DTG+RPV cART

ASPIRE, 2018 USA open-label 48wks 48wks 89 DTG+3TC cART

DOLAM, 2018b Spain open-label 24wks 24wks 60 DTG+3TC cART

GS-US-380-1844, 2018 Multinational double-blind 48wks 48wks 563 DTG+ABC+3TC BIC+TAF+FTC

Subtotal 2704

(2) Naive:

SPRING-1, 2012 Multinational open-label 96wks 48wks 101 DTG+2NRTI EFV+2NRTI SPRING-2, 2013 Multinational double-blind 96wks 48wks 822 DTG+2NRTI RAL+2NRTI SINGLE, 2013 Multinational double-blind 144wks 48wks 833 DTG+ABC+3TC EFV+TDF+FTC FLAMINGO, 2014 Multinational open-label 96wks 48wks 484 DTG+2NRTI DRV/r+2NRTI GS-US-380-1489, 2017 Multinational double-blind 144wks 48wks 629 DTG+ABC+3TC BIC+TAF+FTC GS-US-380-1490, 2017 Multinational double-blind 144wks 48wks 645 DTG+TAF+FTC BIC+TAF+FTC ARIA, 2017c Multinational open-label 48wks 48wks 495 DTG+ABC+3TC ATV/r+TDF+3TV

Paul, 2017 USA double-blind 48wks 48wks 98 DTG+TAF+FTC BIC+TAF+FTC

NAMSAL, 2018 Cameroon open-label 48wks 48wks 613 DTG+TDF+3TC EFV400+TDF+3TC

Table 2: Characteristics of patients included in the selected randomized control trial studies (continued)

DolPHIN-1, 2018d Africa open-label 2weeks postpartum

2weeks

postpartum 60 DTG+2NRTI EFV+2NRTI

INSPIRING, 2018e Multinational open-label 48wks 48wks 113 DTG+2NRTI EFV+2NRTI

Subtotal 4893

(1) Treatment-Experienced:

SAILING, 2013 Multinational double-blind 48wks 48wks 715 DTG+OBR RAL+OBR

DAWNING, 2019 Multinational open-label 48wks 48wks 624 DTG+OBR LPV/r+OBR

Subtotal 1339

NRTI, Nucleoside reverse transcriptase inhibitors; PI/s, ritonavir-boosted protease inhibitor; RPV, Rilpivirine; 3TC, lamivudine;

ABC, abacavir; FTC, emtricitabine; BIC, bictegravir; TAF, Tenofovir alafenamide; DRV/r, darunavir/ritonavir; ATV/r,

Atazanavir/ ritonavir; EFV, Efavirenz; EFV400, 400mg Efavirenz; RAL, raltegravir; LPV/r, lopinavir/ritonavir; cART, current ART regimen;

OBR, investigator-selected optimized backbone regimen.

a In total, 74% patients with a Framingham CVD risk score 10-year risk score more than 10%.

b This study included three different treatment arms with DTG dual- and mono-therapy.

c Eligible patients in this study were only women who aged 18 years or older, pregnant women were excluded.

d This study included Pregnant HIV positive women, initiated ART in third trimester of pregnancy, who randomised to receive DTG or EFV until two weeks postpartum.

e This study enrolled HIV-1 infected ART-naive patients with drug-sensitive tuberculosis, who allocated to DTG arm and received 50 mg twice-daily during and 2 weeks post-tuberculosis therapy, then 50 mg once-daily.

Table 3: Summary of findings: certainty of evidence for HIV virally suppressed patients

Patient or population: HIV virally suppressed patients Setting: all settings

Intervention: Dolutegravir-based

Comparison: others combination antiretroviral therapy

Outcomes

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio

GRADE Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the

相關文件